Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Knox, J J; Barrios, C H; Kim, T M; Cosgriff, T; Srimuninnimit, V; Pittman, K; Sabbatini, R; Rha, S Y; Flaig, T W; Page, R D; Beck, J T; Cheung, F; Yadav, S; Patel, P; Geoffrois, L; Niolat, J; Berkowitz, N; Marker, M; Chen, D; Motzer, R J

Knox, J J; Barrios, C H; Kim, T M; Cosgriff, T; Srimuninnimit, V; Pittman, K; Sabbatini, R; Rha, S Y; Flaig, T W; Page, R D; Beck, J T; Cheung, F; Yadav, S; Patel, P; Geoffrois, L; Niolat, J; Berkowitz, N; Marker, M; Chen, D; Motzer, R J.

Ann Oncol ; 29(11): 2269, 2018 11 01.

Article en En | MEDLINE | ID: mdl-29390043

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290878
https://dx.doi.org/10.1093/annonc/mdx807

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290878
https://dx.doi.org/10.1093/annonc/mdx807

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article